Literature DB >> 31019168

Tumor Necrosis Factor-α Gene Polymorphism (G-308A) and Dilated Cardiomyopathy.

Min Chen1,2, Yu-Feng Jiang1, Hua-Jia Yang1, Nan-Nan Zhang1, Qing Rui1, Ya-Feng Zhou1.   

Abstract

The issue that genetic polymorphism of tumor necrosis factor-α (TNF-α) is associated with dilated cardiomyopathy (DCM) is debatable. We sought to investigate the potential role of TNF-α gene polymorphism (G-308A) in the susceptibility to dilated cardiomyopathy.We retrieved PubMed, EMBASE, and CNKI to collect all articles which reported on the association between TNF-α G-308A polymorphism and dilated cardiomyopathy. Two authors used the Newcastle-Ottawa Scale (NOS) checklist to assess the quality of the included studies. The odds ratio (OR) with 95% confidence intervals (CI) were pooled in a specific genetic model to assess the association and Stata version 14.0 software was used.A total of 9 studies with 1338 patients and 1677 controls were included in this study. The results from this meta-analysis indicated that TNF-α G-308A polymorphism significantly increased the risk of dilated cardiomyopathy in heterozygous comparison (GA versus GG: OR = 1.87; 95%CI = 1.03-3.40; P < 0.05). The increased risk of DCM was also found in Asian populations using a dominant model and heterozygous comparison (GA+AA versus GG: OR = 2.00, 95%CI = 1.02-3.92, P < 0.05; GA versus GG: OR = 1.94, 95%CI = 1.23-3.06, P < 0.05).The current meta-analysis revealed that TNF-α gene polymorphism (G-308A) may be associated with the susceptibility to DCM.

Entities:  

Keywords:  Gene variant; Meta-analysis

Mesh:

Substances:

Year:  2019        PMID: 31019168     DOI: 10.1536/ihj.17-293

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  3 in total

1.  Development and verification of the nomogram for dilated cardiomyopathy gene diagnosis.

Authors:  Li-Qiang Zhou; Chuan Liu; Yeqing Zou; Zhi-Qing Chen
Journal:  Sci Rep       Date:  2022-05-26       Impact factor: 4.996

Review 2.  Well-Known and Novel Serum Biomarkers for Risk Stratification of Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Larisa Anghel; Radu Sascău; Ioana Mădălina Zota; Cristian Stătescu
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 3.  The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy.

Authors:  Ayat Kadhi; Fathima Mohammed; Georges Nemer
Journal:  Front Cardiovasc Med       Date:  2021-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.